Through in-vitro experiments on a biobank of bacteria, the researchers evaluated whether the ivacaftor and lumacaftor modulators had an antibacterial activity, in addition to the action they have on CFTR. Researchers have shown that ivacaftor and lumacaftor have an antibacterial effect against S. aureus and also have a synergistic action with antibiotics and anti-Pseudomonas aeruginosa compounds. Tezacaftor, on the other hand, did not show antimicrobial activity and did not increase the efficacy of antibiotics. It is worth pointing out that ivacaftor and lumacaftor modify the virulence of P. aeruginosa which interferes with the CFTR functionality in the cells of the respiratory epithelium. The researchers also report that in experiments conducted on mice, infections are able to modulate the concentration of ivacaftor. These results can be used to improve the clinical procedure for administering modulators and antibiotics in CF patients chronically infected by P. aeruginosa e S. aureus.